CR20170280A - Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas - Google Patents

Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas

Info

Publication number
CR20170280A
CR20170280A CR20170280A CR20170280A CR20170280A CR 20170280 A CR20170280 A CR 20170280A CR 20170280 A CR20170280 A CR 20170280A CR 20170280 A CR20170280 A CR 20170280A CR 20170280 A CR20170280 A CR 20170280A
Authority
CR
Costa Rica
Prior art keywords
dengue
vaccine
dengue virus
vaccine compositions
methods
Prior art date
Application number
CR20170280A
Other languages
English (en)
Inventor
R Danilo Casimiro
Andrew Bett
Griswold Coller Beth-Ann
Chintala Ramesh V
Govindarajan Dhanasekaran
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20170280A publication Critical patent/CR20170280A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a composiciones de vacuna para el virus del dengue que comprenden una primera y una segunda vacuna para el dengue, en las que la primera vacuna para el dengue comprende al menos un virus del dengue atenuado vivo o virus del dengue quimérico atenuado vivo y la segunda vacuna para el dengue es una vacuna de subunidad para el dengue recombinante, una vacuna de ADN, una vacuna de conjugado, o una vacuna para el dengue inactivada; en las que el genoma del virus del dengue atenuado vivo o el virus quimérico atenuado vivo del dengue comprende una deleción de 30 nucleótidos de la estructura en tallo-bucle de TL2 de la región no traducida en 3¿. Las composiciones de vacuna para el virus del dengue de la invención pueden comprender además uno o más adyuvantes. En realizaciones preferidas de la invención, la primera y la segunda vacuna para el dengue son tetravalentes. La invención también se refiere a procedimientos de uso de las composiciones de vacuna para el virus del dengue de la invención para tratar o prevenir la infección por el dengue, o para prevenir, mejorar o retrasar la aparición o progresión de las manifestaciones clínicas de la misma.
CR20170280A 2014-12-22 2015-12-18 Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas CR20170280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095331P 2014-12-22 2014-12-22
PCT/US2015/066549 WO2016106107A2 (en) 2014-12-22 2015-12-18 Dengue virus vaccine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20170280A true CR20170280A (es) 2017-08-21

Family

ID=56151628

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170280A CR20170280A (es) 2014-12-22 2015-12-18 Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas

Country Status (15)

Country Link
US (1) US10449243B2 (es)
EP (1) EP3236997A4 (es)
JP (1) JP2018502080A (es)
CN (1) CN106999568A (es)
AU (1) AU2015369875A1 (es)
BR (1) BR112017013270A2 (es)
CL (1) CL2017001595A1 (es)
CO (1) CO2017005830A2 (es)
CR (1) CR20170280A (es)
MX (1) MX2017008342A (es)
MY (1) MY192543A (es)
NI (1) NI201700080A (es)
PH (1) PH12017501165A1 (es)
SG (1) SG11201704942QA (es)
WO (1) WO2016106107A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143817A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Dengue virus vaccine
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
SG11202005251VA (en) 2017-12-07 2020-07-29 Merck Sharp & Dohme Formulations of dengue virus vaccine compositions
CA3141460A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0836090A1 (en) 1996-10-12 1998-04-15 Evotec BioSystems GmbH Method of analysis of samples by determination of the distribution of specific brightnesses of particles
DE69841690D1 (de) 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
DE69942525D1 (de) 1998-09-02 2010-08-05 Us Government Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
WO2000057907A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
EP1165129A1 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-4 virus vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
CA2365411A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
DK2292802T3 (en) 2001-05-22 2015-03-09 Us Gov Health & Human Serv Development of mutations useful for attenuation of dengue viruses and chimeric dengue viruses
EP1471873A4 (en) 2002-01-15 2005-03-16 Acambis Inc VACCINES AGAINST FLAVIVIRUS
DE60334310D1 (de) 2002-05-03 2010-11-04 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
CA2549173A1 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
EA015907B1 (ru) 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
DE602006015807D1 (de) 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
EP1896069B1 (en) 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
US8017754B2 (en) 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AR061197A1 (es) 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
USRE46042E1 (en) 2006-08-15 2016-06-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Development of dengue virus vaccine components
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2086526B1 (en) 2006-11-09 2014-07-23 The United States Of America As Represented By The Secretary of the Navy Induction of an immune response against Dengue virus using prime-boost approach
US8440202B2 (en) 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
BR112013009649A2 (pt) * 2010-10-29 2016-07-12 Merck Sharp & Dohme composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
WO2012065105A2 (en) 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina

Also Published As

Publication number Publication date
WO2016106107A2 (en) 2016-06-30
AU2015369875A1 (en) 2017-06-15
US10449243B2 (en) 2019-10-22
BR112017013270A2 (pt) 2018-03-06
NI201700080A (es) 2017-07-18
WO2016106107A3 (en) 2016-08-18
JP2018502080A (ja) 2018-01-25
CL2017001595A1 (es) 2018-01-26
SG11201704942QA (en) 2017-07-28
PH12017501165A1 (en) 2017-12-11
US20170360917A1 (en) 2017-12-21
CN106999568A (zh) 2017-08-01
EP3236997A2 (en) 2017-11-01
EP3236997A4 (en) 2018-05-30
MY192543A (en) 2022-08-26
MX2017008342A (es) 2017-10-24
CO2017005830A2 (es) 2017-08-31

Similar Documents

Publication Publication Date Title
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
BR112015021884A2 (pt) vetores compreendendo sequências de polinucleotídeos de stuffer/agente de enchimento e métodos de uso
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
BR112012023234A2 (pt) vacina de circovírus vivo atenuado quimérico porcino
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
PH12015502666B1 (en) Dengue virus vaccine compositions and methods of use thereof
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
EA201390812A1 (ru) Лиофилизированные вирусные составы
AR101814A1 (es) Partícula de tipo virus flavivirus
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
WO2014140166A3 (en) Vaccine
EA201291179A1 (ru) Органические пероксидные соединения для инактивации микроорганизмов
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201390452A1 (ru) Вакцина
AR102614A1 (es) COMPOSICIONES DE ARNi DEL VIRUS DE HEPATITIS D (HDV) Y MÉTODOS PARA SU USO
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina